Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the United States and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US.
Julie is well published, having authored more than 30 publications in peer-reviewed journals and more than 60 peer-reviewed abstracts presented as posters at major scientific congresses.
00:00 Julie’s earlier episode - EP144 - the “prequel” to this episode.
01:45 Innovative contracting and outcomes based agreements.
02:00 Real World Data vs Real World Evidence.
03:15 The reason behind the Real World Data lag in health care.
03:35 Value-based pricing.
05:00 Who has the best information on a specific product according to who owns patient population Real World Data.
05:45 What Real World Evidence is, and how it differs from Real World Data.
06:15 How Real World Evidence stems from Real World Data.
07:20 Who hires these organizations and how they fit into the value chain.
09:10 Leveraging this data into workflows.
10:30 How pharma companies will utilize Real World Data.
13:35 Are pharma manufacturers being affected by Real World Evidence or Real World Data?
16:00 Is needing Real World Evidence becoming more prominent to US health care?
18:25 The different types of data and how that affects what sorts of conclusions various payers can come to.
21:30 The current gap for physicians at the point of care.
28:25 “Collaboration is a core skill.”
29:15 “You need to first ask around - you don’t know what you don’t know.”
30:25 “One of the most important things early on is just to listen.”
32:30 Genesis Research and their work.
Related Episodes
EP476: Talking Whistleblowing and the Pharma Rebates Whistleblower Case With an Actual Whistleblower, With Ann Lewandowski
Alright, first off, let me calm down any attorneys right outta the gate here. We will not be talking about—at all—the legal activity that is currently ongoing that my guest today, Ann Lewandowski, is involved with. The suit mostly on our radar today is the one where an EBC (employee benefit consult...
EP475: Is This a Moment or a Movement? With Peter Hayes
I was talking to Peter Hayes, my guest this week; and I said, “Peter, you post a lot about many, many different topics on LinkedIn and elsewhere. If you had to roll up all of your posts into a few main, I don’t know, change-making vectors or forces of change, roads to Damascus, what would they be? ...
EP474: Private Equity in Healthcare—The Big Data Points You Really Need to Know, All Together in One Episode, With Yashaswini Singh, PhD
Lots of talk and lots of research these days about private equity in healthcare, so I am so pleased to bring you Yashaswini Singh, PhD, who is one of the authors of a lot of that research. Dr. Yashaswini Singh has been spending the last several years trying to understand the corporate transformatio...